Pathway Gynaecology Cancer & Diagnostic Protocol for Inter Trust transfer

Similar documents
Gynaecology Cancer Red Flags. Dr Dina Bisson Consultant Obstetrician and Gynaecologist Southmead Hospital North Bristol NHS Trust 27 April 2017

Cervical Cancer - Suspected

GP Guidelines for the Management of Adult Patients with Gynaecological Cancers 2012

Health Board/Region: All-Wales

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

Gynaecological Oncology Unit Lead

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs. Gynaecological sarcomas Version 1

Guideline for the Management of Vulval Cancer

Guideline for the Assessment, Management and Referral of Patients with Suspected Ovarian Cancer

CA125 in the diagnosis of ovarian cancer: the art in medicine

Gynaecological cancers. Mr Vivek Nama MD MRCOG Consultant Gynaecological Oncologist

Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122

What is endometrial cancer?

Ovarian cancer. Quick reference guide. Issue date: April The recognition and initial management of ovarian cancer

Primary Care Gynaecology Guidelines: HEAVY REGULAR MENSTRUAL BLEEDING

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Guideline for the Follow-up of Patients with Gynaecological Malignancies

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

Postmenopausal bleeding (PMB) guidelines for women with abnormal vaginal bleeding

Faster Cancer Treatment Indicators: Use cases

Cancer of Unknown Primary (CUP) Protocol

Bladder Cancer Guidelines

Cervical cancer presentation

Gynaecological Oncology Cases

All referrals for out-patient appointments can also be discussed with the Obstetrics and Gynaecology registrar as necessary. Presence of ascites

Appendix 4 Urology Care Pathways

Single Suspected Cancer Pathway Definitions pathway start date

Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE

SUBSPECIALIST TRAINING PROGRAMME

Uterine sarcoma. Information for patients Gynaecology

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

Coversheet for Network Site Specific Group Agreed Documentation

NICE Quality Standards and COF

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

GUIDELINES FOR THE MANAGEMENT OF GYNAECOLOGICAL CANCER

Heavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist

National Optimal Lung Cancer Pathway

The National Framework for Gynaecological Cancer Control

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

Gynae Cancer Multi Disciplinary Team Patient Information

Referral and Management Guidelines for Gynaecological Cancers within North Trent

Clinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network

GYNAECOLOGY PATHWAY BOARD CONSTITUTION JULY 2014

Resource document for LHBs, Trusts and their MDTs Gynaecological cancer follow up: evidence for efficacy of interventions in surveillance

Improving services for upper GI (OG) cancer Application template (Version 2)

Work Programme/Service Delivery Plan 2010/2013

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

LCA Gynaecological Cancer Clinical Guidelines

Gynecology Oncology Rotation

Fertility Assessment and Treatment Pathway

Cancer of Unknown Primary (CUP)

One of the commonest gynecological cancers,especially in white Americans.

Audit Report Report of the 2010 Clinical Audit Data

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Fertility Assessment and Treatment Pathway

Out Patient Hysteroscopy Unit GUIDELINES

REFERRAL GUIDELINES: GYNAECOLOGY

Abnormal uterine bleeding:

Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer

2016 Uterine Cancer Annual Report

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

How can we facilitate cross-boundary working in Greater Manchester?

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary

Aneurin Bevan University Health Board Breast Cancer and Pregnancy Guideline

Case Scenario 1. History

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

Specialised Services Policy: CP02 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Cytoreductive Surgery for treatment of Pseudomyxoma Peritonei

PRIORITIES AND CLINICAL EFFECTIVENESS FORUM

Menstrual Disorders & Ambulatory Gynaecology

Delivering 62 Day GP Cancer Waits in a Complex Landscape. Hannah Marder Cancer Manager University Hospitals Bristol

Richard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead

RAISING THE AWARENESS OF GYNAECOLOGICAL CANCER. Penny Bognuda CNS Gynaecologic Oncology ADHB. June 2015.

Abnormal Uterine Bleeding. Richard Dover Specialist gynaecologist

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

Cancer Care Kenya Notes for General Practioners:

Dr John Short. Obstetrician and Gynaecologist Christchurch Women s Hospital Oxford Women's Health Christchurch

Evaluation of the Infertile Couple

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

Gynecological Cancers

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Vagina. 1. Introduction. 1.1 General Information and Aetiology

Hampshire Hospitals NHS Foundation Trust Guidelines for Justification of Ultrasound Requests January 2019

bleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the

Healthcare Improvement Scotland First published May 2014

Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012

Updates in Gynecologic Oncology. Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018

Identifying distinguishing features of the MDC model within the five ACE projects

Enterprise Interest None

Vaginal intraepithelial neoplasia

Guidelines for Management of Penile Cancer

Audit Report Report of the 2012 Clinical Audit Data

Coversheet for Network Site Specific Group Agreed Documentation

Endometrial Cancer. Incidence. Types 3/25/2019

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health and social care directorate. Quality standards and indicators.

West Midlands Sarcoma Advisory Group

There are a number of national guidelines and performance standards which support the implementation of a straight to CT pathway.

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

West Midlands Sarcoma Advisory Group

National Cancer Programme. Work Plan 2014/15

National Breast Cancer Audit next steps. Martin Lee

Transcription:

NICaN Pathway Gynaecology Cancer & Diagnostic Protocol for Inter Trust transfer Timed schedules to enable the proactive management of the patient from point of receipt of referral to first definitive treatment were drafted. Document history Version 1 - June 2003. Version 2 February 2007 distributed for consultation (closing 12 th March 2007). Version 3 March 2007 Version 4 Version 3 amended to include timed schedules; distributed for consultation closing 29 th November 2007. Version 5 Care Pathway December 2007 DRAFT V5: Last modified 30/11/07 Page 1 of 8

Referral Guidance Gynaecological Cancer Care Pathway: Typical Presentation, Diagnosis and ment Refer patients with symptoms suggestive of gynaecological cancer to an appropriate specialist team. Lesions suspicious of cervical or vaginal cancer on speculum examination (smear not needed) Unexplained vulval lump Vulval bleeding due to ulceration Postmenopausal bleeding with no HRT Postmenopausal bleeding on tamoxifen Postmenopausal bleeding persisting for 6 weeks after stopping HRT NICaN MULTIDISCIPLINARY TEAM MANAGEMENT (ALL PATIENTS SHOULD BE DISCUSSED AT AN MEETING PRE-MANAGEMENT WHERE POSSIBLE) (I.E;STAGING OF DISEASE; NATURE & LOCATION OF TREATMENT) DECISION TO TREAT (DATE PATIENT INFORMED OF TREATMENT AND AGREES TO TREATMENT PLAN) (TIME 31 DAYS) PRIMARY TREATMENT (TIME 62 DAYS) CONTINUING CARE AND FOLLOW-UP SHOULD BE AGREED BY THE CANCER CENTRE / CANCER UNITS S (TIME 0 DAYS) Ovarian cancer is difficult to diagnose. In patients with vague unexplained abdominal symptoms carry out an abdominal palpation. Consider pelvic examination and Ca125 blood test. Refer for urgent USS with palpable abdominal or pelvic mass (not obvious fibroid uterus) where direct access USS is available otherwise make urgent referral. Consider referral if persistent intermenstrual bleeding with normal pelvic examination REFER TO CONSULTANT GYNAECOLOGIST FOR INVESTIGATION/DIAGNOSIS Ovary Cervix Vulva/Vagina Uterus Investigation and Diagnosis Primary ment Continuing Care USS/CT/Ca 125/CEA/C19.9 Risk of Malignancy Index (RMI) calculated Cancer Unit Cancer Centre Radical / Chemotherapy All patients should receive information and literature on community based support. Most palliative care provided by primary care team. Refer as appropriate at any stage for psychosexual counselling or specialist palliative care. Cervical Biopsy Cancer Centre Only Radical Hysterectomy or Chemo-radiation SPECIALIST PALLIATIVE CARE Physical: uncontrolled pain; intestinal obstruction; lymphoedema; drug side effects Psychological:complex emotional issues Rehabilitation Biopsy CT Cancer Centre Only Radical Vulvectomy Social: complex family issues Spiritual: loss of hope; cultural or religious issues Respite Care Terminal Care Hysteroscopy/Biopsy Cancer Unit Hysterectomy+ BSO (early stage low risk disease) Cancer Centre Hysterectomy+BSO+/-Radiotherapy PSYCHOSEXUAL COUNSELLING Severe adjustment reaction to the diagnosis of cancer or the effect of treatment Physical complications affect normal sexual function Psychosexual difficulties directly or indirectly related to disease. DRAFT V3: For consultation; last modified 07/09/07 Page 2 of 8

NICaN GYNAE CANCER - SECONDARY TO TERTIARY REFERRAL Diagnostics Protocol For Inter Trust Transfer INTRODUCTION Priorities for Action 2007/08 targets introduced this year aim to improve the timeliness of access to services for cancer patients. By March 2008, at least 98% of patients diagnosed with cancer should commence treatment within 31 days of the decision to treat. By March 2008 at least 75% of patients urgently referred with a suspected cancer should begin their first definitive treatment within 62 days (increasing to 95% by March 2009). Central to the delivery on this target will be effective and timely transfer of those patients that require a tertiary referral. This will be supported through effective s; by avoiding delay and duplication of diagnostic and staging tests; ensuring that there are no gaps or conflicting pathways operating in organisations along the patient pathway; and proactive patient tracking. It has been agreed with the DHSS&PS Service Delivery Unit that all referrals to tertiary care for treatment should be made within 28 days of receipt of referral as a suspect cancer. This should be possible for the majority of patients. The protocol outlines the clinical investigations that need to be completed before transfer to the tertiary centre in order to enable the service to meet the targets and to ensure that patients have a quality, timely and effective experience at all stages of their pathway. Figure 1 outlines the diagnostic procedures that should be undertaken by Cancer Units prior to referral to the tertiary centre. Immediately the diagnosis has been confirmed histologically Cancer Units should make arrangements for the results of these investigations to be presented at next (Wednesdays at 8.30am) and to be forwarded with the tertiary referral. DRAFT V3: For consultation; last modified 07/09/07 Page 3 of 8

NICaN FIGURE 1. INVESTIGATIONS TO BE COMPLETED AT CANCER UNIT TO BE FORWARDED WITH TERTIARY REFERRAL Cervical Vulval Endometrial Ovarian Biopsy with histology review. Staging procedure - this may be carried out by a special interest clinician at a Cancer Unit. * will usually be carried out at the Cancer Centre. Biopsy with histology results. Anaesthetic assessment as appropriate CT Scan of Pelvis/Abdomen/Chest - may be done at Cancer Unit or at Centre. of pelvis if suspicion of pelvic node involvement may be completed at Unit (following appropriate protocols) or at Centre. Hysteroscopy/ biopsy with histology results. (following appropriate protocols). Anaesthetic Assessment as appropriate Abdominal Ultrasound & CA125 - use these to calculate the Risk of Malignancy Index (RMI) CEA, C19.9 CT of Pelvis / Abdomen / Chest Peritoneal/Pleural tap or Core Biopsy with histology results - may be required where there is doubt regarding the primary origin of the tumour (special histological stains may be sought also). To be completed at Unit where facility is available Anaesthetic fitness assessment as appropriate DRAFT V3: For consultation; last modified 07/09/07 Page 4 of 8

CARE PATHWAY CERVICAL CANCER RECEIPT OF GP REFERRAL / OTHER POINT OF ENTRY 10 days Patient attends OPA / Biopsy Diagnostics to be completed at Unit prior to referral to tertiary centre Biopsy with histology review Staging procedure - this may be carried out by a special interest clinician at a Cancer Unit. * will usually be carried out at the Cancer Centre. Inter trust transfer by day 28* EUA/Staging Mandatory points for holistic assessment and onward referral 6 14 days Palliative care Radiotherapy Chemotherapy * Referral to centre is not dependent upon completion of other investigations DRAFT V3: For consultation; last modified 07/09/07 Page 5 of 8

CARE PATHWAY OVARIAN CANCER RECEIPT OF GP REFERRAL / OTHER POINT OF ENTRY 10 days OPD visit: Tumour markers / USS; RMI CT Scan (if required) Diagnostics to be completed at Unit prior to referral to tertiary centre Abdominal Ultrasound & CA125 - use these to calculate the Risk of Malignancy Index (RMI) CEA, C19.9 CT of Pelvis / Abdomen / Chest Peritoneal/Pleural tap or Core Biopsy may be required where there is doubt regarding the primary origin of the tumour (special histological stains may be sought also) to be completed at Unit where facility is available Anaesthetic fitness assessment as appropriate Inter trust transfer by day 28 Mandatory points for holistic assessment and onward referral 6 *Complex patient - Biopsy * Complex patient patient who requires peritoneal/pleural tap or Core Biopsy due to doubt regarding the primary origin of the tumour. 2 days Appropriate referral Up to 28 days 31 days 31 days Palliative care Chemotherapy Up to 28 days 28 days Palliative care Chemotherapy DRAFT V3: For consultation; last modified 07/09/07 Page 6 of 8

CARE PATHWAY ENDOMETRIAL CANCER RECEIPT OF GP REFERRAL / OTHER POINT OF ENTRY 14 days Patients attends PMB Clinic; USS, Biopsy Hysteroscopy 28 days 28 days 28 days Palliative care Radiotherapy Diagnostics to be completed at Unit prior to referral to tertiary centre Hysteroscopy/ biopsy (following appropriate protocols). Anaesthetic Assessment as appropriate Inter trust transfer by day 28 Mandatory points for holistic assessment and onward referral 6 DRAFT V3: For consultation; last modified 07/09/07 Page 7 of 8

CARE PATHWAY VULVAL CANCER RECEIPT OF GP REFERRAL / OTHER POINT OF ENTRY 14 days Patient attends OPA max Biopsy Diagnostics to be completed at Unit prior to referral to tertiary centre Biopsy with histology results Anaesthetic assessment as appropriate CT Scan of Pelvis/Abdomen/Chest - may be done at Cancer Unit or at Centre. of pelvis if suspicion of pelvic node involvement may be completed at Unit (following appropriate protocols) or at Centre. 22 days Inter trust transfer by day 28 Mandatory points for holistic assessment and onward referral 6 Palliative care Radiotherapy DRAFT V3: For consultation; last modified 07/09/07 Page 8 of 8